Novo Nordisk Reports 'Positive'Phase 3 Results for Etavopivat in Sickle Cell Disease
20 april, 12:16
06:16 AM EDT, 04/20/2026 (MT Newswires) -- Novo Nordisk (NVO) reported Monday "positive"topline results from its Phase 3 HIBISCUS trial, with etavopivat meeting both primary endpoints in sickle cell disease, significantly reducing vaso-occlusive crises and improving haemoglobin levels versus placebo.
The trial showed a 27% reduction in annualised VOC rates and an extended time to first crisis, while 48.7% of patients on etavopivat achieved a haemoglobin increase of more than 1 g/dL at 24 weeks, compared with 7.2% on placebo.
Novo Nordisk said it plans to seek initial regulatory approval for the drug in the second half of 2026, positioning it as a potential first-in-class treatment for a disease affecting millions worldwide.
Ämnen i artikeln
Novo Nordisk Reports 'Positive'Phase 3 Results for Etavopivat in Sickle Cell Disease
20 april, 12:16
06:16 AM EDT, 04/20/2026 (MT Newswires) -- Novo Nordisk (NVO) reported Monday "positive"topline results from its Phase 3 HIBISCUS trial, with etavopivat meeting both primary endpoints in sickle cell disease, significantly reducing vaso-occlusive crises and improving haemoglobin levels versus placebo.
The trial showed a 27% reduction in annualised VOC rates and an extended time to first crisis, while 48.7% of patients on etavopivat achieved a haemoglobin increase of more than 1 g/dL at 24 weeks, compared with 7.2% on placebo.
Novo Nordisk said it plans to seek initial regulatory approval for the drug in the second half of 2026, positioning it as a potential first-in-class treatment for a disease affecting millions worldwide.
Ämnen i artikeln
Analys
Rapporter
